Ascat 2022: Chairman's Address

This year marks the second joint conference with the European Hematology Association (EHA) and the British Society of Haematology (BSH) and nevertheless, with the challenges posed by COVID -19 we are excited to be connecting again in January for what will be a great showcase!

We would like to express our sympathy to those who have been impacted in any way during this COVID-19 pandemic. On behalf of EHA and BSH also, I would like to acknowledge the collective efforts and work that has been done to keep our patients and families safe.

I am pleased to introduce this year’s theme :

Improving the lives of people living with Sickle Cell Disease and Thalassaemia: A focus on new therapies and person-centered care.

This theme reflects on the importance of the welfare of our patients and their families in spite of the progress in research for new drug therapies and curative therapies. The fact that majority of patients with Sickle Cell Disease and Thalassaemia live in low resource settings where these new therapies may not be readily accessible or even affordable, means that we must therefore refocus our attention to improve Newborn Screening and Comprehensive Care, Hydroxyurea Therapy, Blood Transfusion and effective Iron Chelation.

I am excited to be working with an expanded steering committee which includes renowned experts in Sickle Cell Disease, Thalassaemia and Psychology.

Keep an eye out over the coming week for details on this upcoming, exciting and new conference programme!

You are now invited now to submit abstracts for ASCAT/EHA/BSH 2022 Virtual Conference, and all selected abstracts will be published in HemaSphere (EHA) journals.

Kind Regards, Professor Baba Inusa (ASCAT)